

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that the correspondence to which this certificate is affixed, including each document referred to therein as being enclosed or submitted therewith, is being deposited with the United States Postal Service with sufficient postage as first class mail addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

By Lewis J. Kreisler  
Lewis J. Kreisler  
Reg. No. 38522

Date: 3/2/04

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Inventor(s):	Robert M. Lorence, et al.	Atty. Ref	18029
Appl. No.:	10/700,143	Group Art Unit:	Not Assigned
Filed:	November 3, 2003	Examiner:	Not Assigned
Conf. No.:	3847	Customer No.:	31976
Title:	TREATING CARCINOID NEOPLASMS WITH THERAPEUTIC VIRUSES		

\* \* \* \* \*

March 2, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450  
Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Examiner is directed to the documents listed on the enclosed Form PTO-1449. A copy of each listed document is enclosed.

Pecora, et al. (2002) reports that a patient with carcinoid malignancy had measurable tumor reduction, although less than 50% of the total tumor burden (Page 2259, right column, bottom). Pecora does not report that the patient had carcinoid syndrome.


The attention of the Examiner is also directed to:

- the Hotte abstract, penultimate paragraph;
- the Hotte slide presentation, pages 4, 9 and 11;
- the Lorence (December 12, 2002) slide presentation page 12;
- the Lorence (November 6, 2002) slide presentation, page 10.

This Communication is being filed within three months of the filing date or before the mailing of a first Office Action on the merits. Consideration of this Statement is respectfully requested.


It is believed that no fee is required in connection with the filing of this Statement. If any fee is required, the Commissioner is hereby authorized to charge the amount of such fee to Deposit Account No. 50-1677.

Respectfully submitted,



Lewis J. Kreisler  
Reg. No. 38522  
Attorney for Applicant(s)

930 Clopper Road  
Gaithersburg, MD 20878  
Phone: (240) 631-2500 x3276  
Facsimile: (240) 683-3794



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/700,143
		Filing Date	November 3, 2003
		First Named Inventor	Robert M. Lorence
		Group Art Unit	1614
		Examiner Name	Not Assigned
Sheet 1	of 1	Attorney Docket Number	18029

NON PATENT PUBLICATIONS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Pecora, et al., "Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients with Advanced Solid Cancers", Journal of Clinical Oncology, Vol. 20, No. 9, May 1, 2002, pages 2251-2266.	
		Hotte, et al., "Prolonged Intravenous Infusion of PV701: Safety Profile and Objective Tumor Responses in a Phase a I Study of Advanced Cancer Patients", Oncolytic Viruses as Cancer Therapeutics, Scientific Program, Banff, Alberta, Canada, March 26-30, 2003, page 23. (Abstract)	
		Hotte, "Prolonged Intravenous Infusion of PV701: Safety Profile and Objective Tumor Responses in a Phase I Study", Oncolytic Viruses as Cancer Therapeutics, Scientific Program, Banff, Canada, March 28, 2003, pages 1-13. (Slide Presentation)	
		Lorence, et al., "Intravenous Administration of PV701, an Oncolytic Virus, in Phase I Studies: Novel Two-Step ..... Advanced Cancer Patients", Eleventh International Conference on Gene Therapy of Cancer, San Diego, California, December 12-14, 2002, page S15-S16. (Abstract No. 039)	
		Lorence, et al., "Phase I Studies of Intravenous Administration of PV701, an Oncolytic Virus, in Patients with Advanced Solid Cancers", Eleventh International Conference on Gene Therapy of Cancer, San Diego, California, December 12, 2002, pages 1-18. (Slide Presentation)	
		Lorence, "Viruses for the Systemic Treatment of Cancer Patients", BioNorth 2002 Conference Program, 9th Annual Ottawa Life Sciences International Conference and Exhibition, Ottawa Congress Centre, Ottawa, Ontario, Canada, November 4-6, 2002, page 70. (Session Abstract)	
		Lorence, "Viruses for the Systemic Treatment of Cancer Patients", BioNorth 2002 Conference Program, 9th Annual Ottawa Life Sciences International Conference and Exhibition, Ottawa Congress Centre, Ottawa, Ontario, Canada, November 6, 2002, pages 1-16. (Slide Presentation)	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

